Annual Report 2017

INCOME   

  Core funding € 335.000 36%
  Membership fees € 15.000 2%
  EFA Projects € 518.000 56%
  EU Projects € 37.626 4%
  Income previous years € 9.843 1%
  Other income € 9.621 1%
 
TOTAL
€ 925.089
 

OPERATING PROGRAMME

Grants € 335.000        %
  AirLiquide € 30.000 9%
  AlkAbello €30.000 9%
  AstraZeneca €30.000 9%
  Boehringer Ingelheim €30.000 9%
  Chiesi € 5.000 1%
  GSK € 30.000 9%
  Novartis € 30.000 9%
  TEVA € 30.000 9%
  Stallergenes € 30.000 9%
  SigAirHandling € 30.000 9%
  Sanofi Genzyme € 30.000 9%
  Regeneron € 30.000 9%
Membership fees € 15.000  
       

PROJECT PROGRAMME

EFA Projects € 518.000,00  
  COPD MOVE GSK € 40.000 8%
  COPD MOVE AstraZeneca € 40.000 8%
  COPD MOVE Novartis € 23.000 4%
  Atopic Eczema Sanofi Genzyme € 176.000 34%
  Atopic Eczema Regeneron € 176.000 34%
  Capacity Building Novartis € 16.500 3%
  Capacity Building Boehringer ingelheim € 16.500 3%
  Interest Group EP Novartis € 10.000 2%
  Interest Group EP ALK Abello € 10.000 2%
  Interest Group EP Stallergens € 10.000 2%